SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naive, early breast cancer

被引：2

作者：

Oliveira, M. ^{[1
]}

Cejalvo Andujar, J. M. ^{[2
]}

Margeli Vila, M. ^{[3
]}

Tolosa Ortega, P. ^{[4
]}

Martinez Saez, O. ^{[5
]}

Salvador Bofill, F. J. ^{[6
]}

Cruz Jurado, J. ^{[7
]}

Barrera, A. M. Luna ^{[8
]}

Arumi De Dios, M. A. ^{[9
]}

Vidal Losada, M. J. ^{[10
]}

Guerra, J. A. ^{[11
]}

Pernas Simon, S. ^{[12
]}

Villacampa Javierre, G. ^{[13
]}

Gonzalez-Farre, B. ^{[14
]}

Sanfeliu Torres, E. ^{[14
]}

Santhanagopal, A. ^{[15
]}

Falato, C. ^{[16
]}

Ferrero Cafiero, J. M. ^{[17
]}

Pascual, T. ^{[17
]}

Prat, A. ^{[18
]}

机构：

[1] Vall Hebron Univ Hosp, Med Oncol Dept, SOLTI, Barcelona, Spain

[2] Hosp Clin Univ Valencia, Dept Med Oncol, SOLTI, Valencia, Spain

[3] Hosp Badalona Germans Trias & Pujol, ICO Inst Catala Oncol Badalona, Med Oncol Dept, SOLTI, Badalona, Spain

[4] Hosp Univ 12 Octubre, SOLTI, Oncol Dept, Valencia, Spain

[5] Hosp Clin Barcelona, SOLTI, Dept Med Oncol, Barcelona, Spain

[6] Hosp Univ Virgen Valme, Med Oncol Dept, Seville, Spain

[7] Hosp Univ Canarias, Med Oncol Dept, Santa Cruz De Tenerife, Canary Islands, Spain

[8] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain

[9] Univ Barcelona, Fac Med, Med Oncol Dept, Barcelona, Spain

[10] Hosp Clin Barcelona, SOLTI, Med Oncol Dept, Barcelona, Spain

[11] Hosp Univ Fuenlabrada, Med Oncol Dept, Fuenlabrada, Spain

[12] Hosp Duran i Reynals, Med Oncol Breast Unit, SOLTI, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain

[13] Vall Hebron Inst Oncol VHIO, Cellex Ctr, Stat Dept, SOLTI, Barcelona, Spain

[14] Hosp Clin Barcelona, Pathol, Barcelona, Spain

[15] Daiichi Sankyo Inc, Res & Dev, Basking Ridge, NJ USA

[16] IDIBAPS August Pi i Sunyer Biomed Res Inst, Translat Genom & Targeted Therapies, Barcelona, Spain

[17] SOLTI HQ, Clin Res Dept, Barcelona, Spain

[18] Hosp Clin Barcelona, IDIBAPS, SOLTI, Dept Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

202TiP

引用

页码：S628 / S628

页数：1

共 50 条

[1] SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
Pascual, Tomas
Oliveira, Mafalda
Ciruelos, Eva
Bellet Ezquerra, Meritxell
Saura, Cristina
Gavila, Joaquin
Pernas, Sonia
Munoz, Montserrat
Vidal, Maria J.
Margeli Vila, Mireia
Cejalvo, Juan M.
Gonzalez-Farre, Blanca
Espinosa-Bravo, Martin
Cruz, Josefina
Salvador-Bofill, Francisco Javier
Guerra, Juan Antonio
Luna Barrera, Ana Maria
Arumi de Dios, Miriam
Esker, Stephen
Fan, Pang-Dian
Martinez-Saez, Olga
Villacampa, Guillermo
Pare, Laia
Ferrero-Cafiero, Juan M.
Villagrasa, Patricia
Prat, Aleix
FRONTIERS IN ONCOLOGY, 2021, 11
[2] Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Braso-Maristany, Fara
Ferrero-Cafiero, Juan Manuel
Falato, Claudette
Martinez-Saez, Olga
Cejalvo, Juan Miguel
Margeli, Mireia
Tolosa, Pablo
Salvador-Bofill, Francisco Javier
Cruz, Josefina
Gonzalez-Farre, Blanca
Sanfeliu, Esther
Odena, Andreu
Serra, Violeta
Pardo, Francisco
Luna Barrera, Ana Maria
Arumi, Miriam
Guerra, Juan Antonio
Villacampa, Guillermo
Sanchez-Bayona, Rodrigo
Ciruelos, Eva
Espinosa-Bravo, Martin
Izarzugaza, Yann
Galvan, Patricia
Matito, Judith
Pernas, Sonia
Vidal, Maria
Santhanagopal, Anu
Sellami, Dalila
Esker, Stephen
Fan, Pang-Dian
Suto, Fumitaka
Vivancos, Ana
Pascual, Tomas
Prat, Aleix
Oliveira, Mafalda
NATURE COMMUNICATIONS, 2024, 15 (01)
[3] Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
Prat, A.
Falato, C.
Pare Brunet, L.
Martinez Saez, O.
Cejalvo Andujar, J. M.
Margeli Vila, M.
Tolosa, P.
Salvador Bofill, F. J.
Cruz Jurado, J.
Gonzalez-Farre, B.
Sanfeliu Torres, E.
Ciruelos, E. M.
Espinosa-Bravo, M.
Izarzugaza Peron, Y.
Pernas Simon, S.
Esker, S.
Fan, P-D.
Ferrero Cafiero, J. M.
Pascual, T.
Oliveira, M.
ANNALS OF ONCOLOGY, 2022, 33 : S164 - S164
[4] Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3)
Prat, Aleix
Cejalvo, Juan M.
Pare, Laia
Martinez-Saez, Olga
Vila, Mireia Margeli
Falato, Claudette
Cruz, Josefina
de Dios, Miriam Arumi
Vidal, Maria J.
Guerra, Juan Antonio
Barrera, Ana Maria Luna
Tolosa, Pablo
Salvador-Bofill, Francisco Javier
Pernas, Sonia
Gonzales-Farre, Blanca
Sanfeliu, Esther
Ciruelos, Eva
Serra, Violeta
Espinosa-Bravo, Martin
Izarzugaza, Yann
Esker, Stephen
Fan, Pang-Dian
Villacampa, Guillermo
Ferrero-Cafiero, Juan M.
Pascual, Tomas
Oliveira, Mafalda
CANCER RESEARCH, 2022, 82 (04)
[5] Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial
Braso-Maristany, Fara
Falato, Claudette
Martinez-Saez, Olga
Cejalvo, Juan Miguel
Margeli, Mireia
Tolosa, Pablo
Bofill, Francisco Javier Salvador
Cruz, Josefina
Gonzalez-Farre, Blanca
Sanfeliu, Esther
Arumi, Miriam
Villacampa, Guillermo
Ciruelos, Eva
Espinosa-Bravo, Martin
Izarzuzaga, Yann
Galvan, Patricia
Matito, Judit
Pernas, Sonia
Santhanagopal, Anu
Esker, Stephen
Patel, Parul
Fan, Pang-Dian
Ferrero-Cafiero, Juan Manuel
Vivancos, Ana
Pascual, Tomas
Prat, Aleix
Oliveira, Mafalda
Ferrero-Cafiero, Juan Manuel
Vivancos, Ana
Pascual, Tomas
Prat, Aleix
Oliveira, Mafalda
CANCER RESEARCH, 2023, 83 (05)
[6] Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study
Oliveira, M.
Falato, C.
Cejalvo, J. M.
Vila, M. Margeli
Tolosa, P.
Salvador-Bo, F. J.
Cruz, J.
Arumi, M.
Luna, A. M.
Guerra, J. A.
Vidal, M.
Martinez-Saez, O.
Pare, L.
Gonzalez-Farre, B.
Sanfeliu, E.
Ciruelos, E.
Espinosa-Bravo, M.
Pernas, S.
Izarzugaza, Y.
Esker, S.
Fan, P. -D
Parul, P.
Santhanagopal, A.
Sellami, D.
Villacampa, G.
Ferrero-Cafiero, J. M.
Pascual, T.
Prat, A.
ANNALS OF ONCOLOGY, 2023, 34 (08) : 670 - 680
[7] Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Koyama, Kumiko
Ishikawa, Hirokazu
Abe, Manabu
Shiose, Yoshinobu
Ueno, Suguru
Qiu, Yang
Nakamaru, Kenji
Murakami, Masato
PLOS ONE, 2022, 17 (05):
[8] Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2-advanced breast cancer (ABC)
Pistilli, B.
Pierotti, L.
Lacroix-Triki, M.
Vicier, C.
Frenel, J-S.
D'Hondt, V.
Dalenc, F.
Bachelot, T.
Ducoulombier, A.
Benderra, M-A.
Loirat, D.
Mayeur, D.
Nachabeh, G. B.
Sporchia, A.
Suto, F.
Michiels, S.
Corcos, N.
Mosele, M. F.
Andre, F.
Montagnac, G.
ANNALS OF ONCOLOGY, 2024, 35 : S357 - S357
[9] Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)
Odena, Andreu
Monserrat, Laia
Braso-Maristany, Fara
Guzman, Marta
Grueso, Judit
Rodriguez, Olga
Scaltriti, Maurizio
Chandarlapaty, Sarat
Qiu, Yang
Koyama, Kumiko
Oliveira, Mafalda
Prat, Aleix
Serra, Violeta
CANCER RESEARCH, 2022, 82 (04)
[10] HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd
Singer, Christian Fridolin
Jahn, Stephan Wenzel
Hlauschek, Dominik
Heber, Ulrike Maria
Mang-Manger, Charlotte
Egle, Daniel
Balic, Marija
Pichler, Angelika
Pfeiler, Georg
Kacerovsky-Strobl, Stephanie
Suppan, Christoph
Ritter, Magdalena
Petru, Edgar
Greil, Richard
Bago-Horvath, Zsuzsanna
Deutschmann, Christine
Steger, Guenther Georg
Seifert, Michael
Fitzal, Florian
Bartsch, Rupert
Santhanagopal, Anu
Machacek-Link, Jana
Sellami, Dalila
Schwarz, Magdalena
Fesl, Christian
Soelkner, Lidija
Esker, Stephen
Filipits, Martin
Gnant, Michael
CANCER COMMUNICATIONS, 2025,

← 1 2 3 4 5 →